Background. Metagenomic next-generation sequencing (mNGS) of CSF can identify nearly all pathogens in a single test. We previously validated a CSF mNGS assay in a licensed clinical laboratory. To date, the utility of mNGS for infectious disease diagnosis has been described in case reports and small case series, but not in a large-scale clinical trial.
Background. The mainstay of malaria diagnosis relies on rapid diagnostic tests (RDT) and Giemsa-stained microscopy both of which lack analytical sensitivity. This leads to repeat testing to rule out malaria. Nucleic acid amplification (NAT) methods are more sensitive, but testing requires technical proficiency beyond the average clinical laboratory.
Methods. We conducted a prospective diagnostic trial of the Meridian illumigene Malaria assay (LAMP) compared with reference microscopy and RDT (BinaxNOW Malaria) in returning travelers in Western Canada between June 2017 and January 2018. Returning travelers with signs and symptoms of fever were enrolled into the study. RDT, microscopy, and LAMP assays were performed simultaneously. To increase the yield of positive specimens for all species of malaria, retrospective specimens of Plasmodium vivax, P. ovale, and P. malariae species were supplemented. Real-time (RT)-PCR testing was performed on all specimens to resolve discrepancies. A cost-benefit analysis was performed.
Results. A total of 296 consecutive patients (50.7% male, mean age 32.5) were enrolled, most visiting friends and relatives (43.2%), traveling to Asia (48.4%), presenting with fever (88.9%), not taking prophylaxis (82.8%), and treated as outpatients (84.3%). In the prospective arm, LAMP had a sensitivity of 98.1% (95% CI 89.9-99.9) and a specificity of 97.6% (95% CI 95.2-99.0) versus microscopy. After discrepant resolution with RTPCR, LAMP had a sensitivity of 100% (95% CI 93.9-100) and a specificity of 100% (95% CI 98.7-100) versus microscopy. When including retrospective specimens, LAMP had a sensitivity of 98.7% (95% CI 92.7-99.9) and a specificity of 97.6% (95% CI 95.2-99.1) versus microscopy, and after discrepant resolution of this set, LAMP had a sensitivity of 100% (95% CI 95.5-100) and a specificity of 100% (95% CI 98.7-100). The rate of invalid tests with LAMP was 3.05%. After discrepant resolution, RDT had a sensitivity of 83.3% (95% CI 58.6-96.4) and a specificity of 96.2% (95% CI 93.2-98.1) versus microscopy. A cost-benefit analysis of reagents and labor suggests up to USD 13 savings per specimen using a revised algorithm with LAMP screening.
Conclusion. A novel, highly sensitive testing algorithm for malaria screening with associated cost savings in the nonendemic setting is proposed.
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